Government hits patent thickets on multiple fronts

Patent thickets are the latest target in lawmakers' bid to lower drug prices.

By Alexandra Pecci • Feb. 5, 2024

Could Novo, Lilly become first trillion-dollar healthcare companies?

Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

By Meagan Parrish • Feb. 2, 2024

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Merck keeps deal focus with Keytruda patent cliff on horizon

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

By Ned Pagliarulo • Feb. 1, 2024

Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.

By Michael Gibney • Feb. 1, 2024

CAR-T developers respond to FDA black box warning

Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

By Kelly Bilodeau • Jan. 30, 2024

Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

By Alexandra Pecci • Jan. 30, 2024

AstraZeneca, Daiichi aim for first pan-tumor ADC approval

A “tumor agnostic” FDA approval for the companies’ Enhertu would break new ground for antibody-drug conjugates. 

By Ben Fidler • Jan. 29, 2024

‘1 plus 1 equals 3’ — the co-CEO model in pharma

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

By Meagan Parrish • Jan. 26, 2024

King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

By Michael Gibney • Jan. 25, 2024

The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

Breast cancer tops list of most studied diseases

The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

By Kelly Bilodeau • Jan. 24, 2024

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

By Michael Gibney • Jan. 24, 2024

The hunt for an elusive universal coronavirus vaccine

A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

By Alexandra Pecci • Jan. 22, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

How to make 2024 a banner year for biopharma, despite the headwinds

Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

By Michael Gibney • Jan. 18, 2024

An enduring COVID mystery: Why some do fine and others die

The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

By Alexandra Pecci • Jan. 17, 2024

Pharma takes a gut check of microbiome drugs

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

By Kelly Bilodeau • Jan. 16, 2024

Pharma execs sound off on trends and policies they’re tracking in 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

By Meagan Parrish • Jan. 12, 2024

4 big FDA approval dates to watch in 2024

Following a year where the FDA approved 55 new drugs, the 2024 PDUFA calendar is set with a number of potentially buzzy approvals. 

By Alexandra Pecci • Jan. 12, 2024

PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials

As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

By Meagan Parrish • Jan. 11, 2024

Believe the hype? Mixed signals from AI’s impact on drug development

Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.

By Kelly Bilodeau • Jan. 10, 2024

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.

By Meagan Parrish • Jan. 9, 2024

How J&J is tackling a ‘secondary pandemic’ in the Black community

J&J is leading a grassroots effort to improve mental health access and care.

By Alexandra Pecci • Jan. 8, 2024

Regulatory twists and turns are coming for biopharma in 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

By Kelly Bilodeau • Jan. 8, 2024

In the post-pandemic era, three players still dominate the infectious disease market

While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.

By Alexandra Pecci • Jan. 5, 2024